Hu Xiao, Wang Zijie, Liu Jincheng, Liu Xueyun, Luo Jiaxin, Meng Zizhen, Yang Tiannan, Li Qi
Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Neurology, Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, China.
Int J Stroke. 2025 Jun 10:17474930251351103. doi: 10.1177/17474930251351103.
The association between statin use and the risk of incident intracerebral hemorrhage (ICH) remains controversial, with concerns about a potential increased risk of ICH among statin users.
This study aimed to investigate the association between statin use and incident ICH in the general population.
This prospective cohort study utilized data from UK Biobank. Cox proportional regression models were employed to estimate hazard ratios (HRs) for the association between statin use and incident ICH in both unmatched and propensity score-matched (PSM) cohorts, adjusting for sociodemographic characteristics, lifestyle factors, comorbidities, and concurrent medication use.
A total of 421,444 participants were included in the final analysis, with a median age of 58.0 years (interquartile range [IQR]: 50.0-63.0), and 53.9% were female. At baseline, 69,272 individuals reported regular statin use. Over a median follow-up period of 12.75 years (IQR: 11.30-14.21), 1533 participants (0.4%) experienced incident ICH. Multivariate Cox regression analyses showed that statin use was significantly associated with a reduced risk of ICH in the fully adjusted model (aHR 0.77; 95% CI 0.66-0.90). This association was significant among individuals without a history of coronary artery disease, stroke or transient ischemic attack (aHR 0.75; 95% CI 0.63-0.89). Potential interaction effects were identified between statin use and age ( for interaction = 0.027 in the total cohort), waist-to-hip ratio, and low-density lipoprotein cholesterol levels ( for interaction = 0.025 and 0.062, respectively, in the PSM cohort) in relation to ICH risk.
In this large population-based study, statin use was associated with a reduced risk of incident ICH, providing further evidence for the long-term safety of statin therapy with respect to ICH risk in the general population and across diverse subgroups.Data access statement:UK Biobank database is available on application by approved researchers.
他汀类药物的使用与脑出血(ICH)发病风险之间的关联仍存在争议,人们担心他汀类药物使用者发生ICH的风险可能增加。
本研究旨在调查普通人群中他汀类药物的使用与ICH发病之间的关联。
这项前瞻性队列研究使用了英国生物银行的数据。采用Cox比例回归模型估计未匹配和倾向评分匹配(PSM)队列中他汀类药物使用与ICH发病之间关联的风险比(HR),并对社会人口统计学特征、生活方式因素、合并症和同时使用的药物进行调整。
共有421444名参与者纳入最终分析,中位年龄为58.0岁(四分位间距[IQR]:50.0 - 63.0),53.9%为女性。在基线时,69272人报告经常使用他汀类药物。在中位随访期12.75年(IQR:11.30 - 14.21)内,1533名参与者(0.4%)发生了ICH。多变量Cox回归分析显示,在完全调整模型中,他汀类药物的使用与ICH风险降低显著相关(校正HR 0.77;95%置信区间0.66 - 0.90)。这种关联在无冠状动脉疾病、中风或短暂性脑缺血发作病史的个体中显著(校正HR 0.75;95%置信区间0.63 - 0.89)。在他汀类药物使用与年龄(总队列中交互作用P = 0.027)、腰臀比以及低密度脂蛋白胆固醇水平(PSM队列中交互作用P分别为0.025和0.062)之间,发现了与ICH风险相关的潜在交互作用。
在这项基于人群的大型研究中,他汀类药物的使用与ICH发病风险降低相关,为他汀类药物治疗在普通人群及不同亚组中关于ICH风险的长期安全性提供了进一步证据。
经批准的研究人员可申请访问英国生物银行数据库。